Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Multiple myeloma is characterized by the growth of plasma cells in the bone marrow and the development of osteolytic bone disease. Myeloma cells are found closely associated with bone, and targeting this environment may therefore affect both the bone disease and the growth of myeloma cells. We have...
Hauptverfasser: | Croucher, P, De Hendrik, R, Perry, M, Hijzen, A, Shipman, C, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Vanderkerken, K |
---|---|
Format: | Journal article |
Sprache: | English |
Veröffentlicht: |
2003
|
Ähnliche Einträge
Ähnliche Einträge
-
Zoledronic acid prevents the development of myeloma bone disease and increases survival
von: Shipman, C, et al.
Veröffentlicht: (2002) -
Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
von: Croucher, P, et al.
Veröffentlicht: (2002) -
Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
von: Croucher, P, et al.
Veröffentlicht: (2001) -
Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
von: Croucher, P, et al.
Veröffentlicht: (2000) -
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
von: Croucher, P, et al.
Veröffentlicht: (2003)